Loading...
Clinicians who treat prostate cancer patients with androgen-deprivation therapy (ADT) are skilled at recognizing and managing adverse effects, such as hot flashes, metabolic syndrome/weight gain, muscle mass loss, and osteoporosis. More difficult to assess and manage is the potential impact of ADT on cognitive function. Compelling data on this topic have been in short supply, but in a high-volume prostate cancer practice a substantial minority of patients report changes in cognitive function, often described as a loss of “sharpness” following ADT.
To assess the effect of ADT on cognitive performance, investigators prospectively studied three groups of individuals: 58 prostate cancer patients receiving ADT, 84 prostate cancer patients not rec…